TF and breast carcinoma: To further validate the disease-specificity of the three biomarkers, we examined serum levels for apoA-I, TTR and TF in 71 additional subjects that included normal (18), breast cancer (18), colon cancer (8), atherosclerosis (9), and early stage OC (18) (Fig. 2).